Psychiatr. pro Praxi, 2010; 11(3): 130-134

Prevention of cardiovascular risk and diabetes in schizophrenia patients: application of internet in clinical praxis

MUDr.Jiří Masopust, Ph.D., MUDr.Radovan Malý, Ph.D.
Psychiatrická klinika LF UK a FN Hradec Králové
1. interní klinika LF UK a FN Hradec Králové

The excess cardiovascular mortality associated with schizophrenia is attributed in part to an increased risk of the modifiable coronary

heart disease factors as obesity, diabetes mellitus, hypertension, dyslipidaemia, and smoking. We describe assessment of these cardiovascular

risk factors using a special webpage.

Keywords: schizophrenia, antipsychotics, cardiovascular risk factors, mortality

Published: July 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Masopust J, Malý R. Prevention of cardiovascular risk and diabetes in schizophrenia patients: application of internet in clinical praxis. Psychiatr. praxi. 2010;11(3):130-134.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64: 1123-1131. Go to original source... Go to PubMed...
    2. Ösby U, Correia N, Brandt L, et al. Time trends in schizophrenia mortality in Stockholm County, Sweden: cohort study. BMJ 2000; 321: 483-484. Go to original source... Go to PubMed...
    3. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based kohort study (FIN11 study). Lancet 2009; 374: 620-627. Go to original source... Go to PubMed...
    4. Conroy RM, Pyörälä K, Fitzgerald AP, et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003. Go to original source... Go to PubMed...
    5. NICE. Schizophrenia Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. 2008; dostupné na: http://www.nice.org.uk/guidance/index.jsp?action=download&=42139.
    6. Češková E, Tůma I, Přikryl R, Pěč O. Schizofrenie. In: Raboch J, Anders M, Praško J, Hellerová P. Psychiatrie. Doporučené postupy psychiatrické péče II. Praha: Infopharm 2006: 54-63.
    7. Seifertová D, Libiger J, Švestka J, et al. Schizofrenie. In: Seifertová D, Praško J, Horáček J, Höschl C. Postupy v léčbě psychických poruch. Algoritmy České neuropsychofarmakologické společnosti. Praha: Medical Tribune CZ; 79-102.
    8. DeHert M, Dekker JM, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009; 24: 412-424. Go to original source... Go to PubMed...
    9. Haupt DW, Rosenblatt LC, Kim E, et al. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 2009; 166: 345-353. Go to original source... Go to PubMed...
    10. Morrato EH, Druss B, Hartung DM, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010; 67: 17-24. Go to original source... Go to PubMed...
    11. Cífková R, Býma S, Češka R, et al. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. Cor Vasa 2005(Suppl); 47: 3-14.
    12. Stahl SM, Mignon L, Meyer JM. Which dones first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009; 119: 171-179. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.